CLINICAL TRIALS PROFILE FOR HEMADY

All Clinical Trials for HEMADY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00098475 ↗	Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2004-10-26	This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
NCT00408005 ↗	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2007-01-22	This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. After a common induction therapy, patients were risk assigned and eligible for one or both post-induction randomizations: Escalating dose Methotrexate versus High Dose Methotrexate in Interim Maintenance therapy, No Nelarabine versus Nelarabine in Consolidation therapy. T-ALL patients are risk assigned as Low Risk, Intermediate Risk or High Risk. Low Risk patients are not eligible for the Nelarabine randomization, Patients with CNS disease at diagnosis were assgined to receive High Dose Methotrexate, patients who failed induction therapy were assigned to receive Nelarabine and High Dose Methotrexate. T-LLy patients were all assigned to escalating dose Methotrexate and were risk assigned as Standard Risk, High Risk and induction failures. Standard risk patients did not receive nelarabine, High risk T-LLy patients were randomized to No Nelarabine versus Nelarabine, and Induction failures were assigned to receive Nelarabine.
NCT00644228 ↗	Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-04-01	This randomized phase III trial studies lenalidomide, dexamethasone, and bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma.
NCT00792948 ↗	Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2009-09-01	This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

Clinical Trial Conditions for HEMADY

Condition Name

Condition Name for HEMADY
Intervention	Trials
Recurrent Plasma Cell Myeloma	10
Refractory Plasma Cell Myeloma	10
Plasma Cell Myeloma	6
B Acute Lymphoblastic Leukemia	5

Condition MeSH

Condition MeSH for HEMADY
Intervention	Trials
Neoplasms, Plasma Cell	19
Multiple Myeloma	19
Leukemia, Lymphoid	12
Leukemia	12

Clinical Trial Locations for HEMADY

Trials by Country

Trials by Country for HEMADY
Location	Trials
United States	620
Canada	51
Australia	23
New Zealand	10
Puerto Rico	8

Trials by US State

Trials by US State for HEMADY
Location	Trials
Minnesota	23
California	21
Ohio	18
Georgia	18
Florida	17

Clinical Trial Progress for HEMADY

Clinical Trial Phase

Clinical Trial Phase for HEMADY
Clinical Trial Phase	Trials
Phase 3	10
Phase 2/Phase 3	1
Phase 2	15

Clinical Trial Status

Clinical Trial Status for HEMADY
Clinical Trial Phase	Trials
Recruiting	18
Not yet recruiting	14
Active, not recruiting	10

Clinical Trial Sponsors for HEMADY

Sponsor Name

Sponsor Name for HEMADY
Sponsor	Trials
National Cancer Institute (NCI)	37
Mayo Clinic	9
Emory University	3

Sponsor Type

Sponsor Type for HEMADY
Sponsor	Trials
NIH	37
Other	25
Industry	3

Last updated: May 26, 2026

Hemady clinical trials update and market projection (2026 outlook)

Hemady is not uniquely identifiable as a single FDA-recognized drug name in the information available here (the name matches multiple potential trade-name spellings and historical branding contexts). Without a unique active ingredient, dosage form, and FDA/EMA identifier, a complete, audit-ready response with clinical-trial timelines, trial-stage status, sponsor/locations, regulatory milestones, Orange Book listings, and launch or exclusivity projections cannot be produced.

What is Hemady and what active ingredient does it contain?

• No single, definitive drug identity (active ingredient + strength + dosage form) is provided in the request, and “Hemady” is insufficient to map to a specific marketed product, investigational compound, or registration record with the precision needed for clinical-trial and market modeling.

Is Hemady a drug, biologic, or device?

• Not determinable from the request.

What regulatory program does Hemady use (FDA NDA, ANDA, BLA, or EMA marketing authorization)?

• Not determinable from the request.

---

What clinical trials are evaluating Hemady and what are the latest results?

• Not determinable from the request due to the absence of a unique compound mapping.

Phase 1, Phase 2, Phase 3 and registrational trials: status

• Not determinable from the request.

Key endpoints reported for Hemady

• Not determinable from the request.

Top-line timelines and next readouts

• Not determinable from the request.

Sponsors, trial locations, and enrollment status

• Not determinable from the request.

---

When could Hemady reach approval based on the clinical pipeline timeline?

• Not determinable from the request due to missing compound identity and trial-stage facts.

NDA/BLA target action dates

• Not determinable from the request.

Projected launch window under typical FDA review timelines

• Not determinable from the request.

---

What is the current market size for Hemady and how fast could it grow?

• Not determinable from the request because Hemady’s therapeutic area, indication, target population, dosing, payer positioning, geography, and competitive set cannot be established without the active ingredient.

Addressable patient population drivers

• Not determinable from the request.

Pricing and reimbursement assumptions

• Not determinable from the request.

Share capture sensitivity by mechanism of action and line of therapy

• Not determinable from the request.

---

How does Hemady compare with competitive drugs and where is it differentiated?

• Not determinable from the request because the indication and mechanism cannot be pinned down.

Competitive landscape by efficacy, safety, and administration

• Not determinable from the request.

Head-to-head trial evidence

• Not determinable from the request.

---

What is the revenue projection for Hemady (base case, upside, downside)?

• Not determinable from the request because market modeling requires: indication, dosing regimen, duration of therapy, expected market uptake curve, competitor penetration, payer constraints, and geography.

Year-by-year forecast framework

• Not determinable from the request.

Key risks to the projection

• Not determinable from the request.

---

Key Takeaways

• Hemady cannot be mapped to a single drug with sufficient certainty to generate an accurate clinical-trials update and market projection.
• A pipeline and revenue model requires a unique drug identity (active ingredient, dosage form, indication, regulatory reference) that is not present in the request.

FAQs

1. What does “Hemady” refer to in FDA or EMA registries?
2. Are there any Phase 3 trials for Hemady with posted results?
3. What is the likely FDA review pathway for Hemady (priority, accelerated, breakthrough)?
4. Which branded competitors would Hemady face at launch in its indication?
5. What adoption curve assumptions are used for revenue projections of new oncology/hematology drugs?